var data={"title":"Levofloxacin (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Levofloxacin (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/389801?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=levofloxacin-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Levofloxacin (systemic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=levofloxacin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Levofloxacin (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8398365\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious adverse reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together, including tendinitis and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue levofloxacin immediately and avoid the use of fluoroquinolones in patients who experience any of these serious adverse reactions. Because fluoroquinolones have been associated with serious adverse reactions, reserve levofloxacin for use in patients who have no alternative treatment options for the following indications: uncomplicated urinary tract infection, acute bacterial exacerbation of chronic bronchitis, and acute bacterial sinusitis.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Exacerbation of myasthenia gravis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Fluoroquinolones may exacerbate muscle weakness in patients with myasthenia gravis. Avoid levofloxacin in patients with a known history of myasthenia gravis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8398376\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Levaquin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8398377\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Levaquin;</li>\n      <li>Levaquin in 5% Dextrose Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8398383\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Fluoroquinolone;</li>\n      <li>\n        Antibiotic, Respiratory Fluoroquinolone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8406522\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Sequential therapy (IV to oral) may be instituted based on prescriber's discretion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute bacterial rhinosinusitis:</b> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: 750 mg every 24 hours for 5 days or 500 mg every 24 hours for 10 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate recommendations: 500 mg every 24 hours for 5 to 7 days (Chow 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthrax (inhalational):</b> Oral, IV: 500 mg every 24 hours for 60 days, beginning as soon as possible after exposure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bite wounds (animal/human) (off-label use):</b> Oral, IV: <b>Note:</b> Recommended as an alternative therapy for human bite wound in patients hypersensitive to beta-lactams: 750 mg once daily; in combination with metronidazole or clindamycin (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Chlamydia trachomatis</i> urogenital infection (alternative to preferred therapy) (off-label use):</b> Oral: 500 mg once daily for 7 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic bronchitis (acute bacterial exacerbation):</b> Oral: 500 mg every 24 hours for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic foot infections, moderate to severe (off-label use):</b> Oral, IV: <b>Note:</b> Initial treatment should begin with an IV regimen for severe infections; moderate infections may initially be treated with IV or oral regimen (IDSA [Lipsky 2012]): 750 mg once daily (Graham 2002); use in combination with clindamycin (limited evidence supporting clindamycin for severe <i>S. aureus</i> infections) (IDSA [Lipsky 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diverticulitis, peritonitis (off-label use) (Solomkin [IDSA] 2010):</b> Oral, IV: 750 mg every 24 hours for 7 to 10 days; use adjunctive metronidazole therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Epididymitis (off-label use; CDC [Workowski 2015]):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Likely caused by enteric organisms:</i> 500 mg once daily for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Likely caused by sexually-transmitted chlamydia and gonorrhea and enteric organisms in men who practice insertive anal sex:</i> 500 mg once daily for 10 days in combination with ceftriaxone</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Helicobacter pylori</i></b> <b>eradication (off-label use):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">American College of Gastroenterology guidelines (Chey 2007; Chey 2017):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Levofloxacin triple regimen</i>: 500 mg once daily, in combination with amoxicillin 1 g twice daily, plus a standard-dose proton pump inhibitor twice daily; continue regimen for 10 to 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infection, complicated, community-acquired (in combination with metronidazole) (off-label use) (Solomkin, [IDSA] 2010):</b> IV: 750 mg once daily for 4 to 7 days (provided source controlled). <b>Note:</b> Avoid using in settings where <i>E. coli</i> susceptibility to fluoroquinolones is &lt;90%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neutropenia (chemotherapy-induced), antibacterial prophylaxis (off-label use): </b>Oral: 500 mg once daily (Bucaneve 2005; Cullen 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pelvic inflammatory disease (in patients allergic to cephalosporins; off-label use):</b> Oral: 500 mg once daily for 14 days with concomitant metronidazole; <b>Note:</b> The CDC recommends use as an alternative therapy only if standard parenteral cephalosporin therapy is not feasible, community prevalence, and individual risk of quinolone-resistant gonococcal organisms is low. Culture sensitivity must be confirmed (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Plague (prophylaxis and treatment): </b> Oral, IV: 500 mg every 24 hours for 10 to 14 days, beginning as soon as possible after exposure. <b>Note:</b> Dose of 750 mg once daily may be considered if clinically warranted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Community-acquired (CAP):</i> Oral, IV: 500 mg every 24 hours for 7 to 14 days or 750 mg every 24 hours for 5 days; <b>Note:</b> CAP guidelines recommend the 750 mg dose (IDSA/ATS [Mandell 2007])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hospital-acquired or ventilator-</i>\n      <i>associated pneumonia:</i> IV: 750 mg every 24 hours for 7 days; may consider shorter or longer duration depending on rate of clinical improvement. When used as empiric therapy, use in combination with an agent active against MRSA (unless coverage of MSSA only is appropriate) with or without an additional antipseudomonal agent (dependent on patient and institution-specific risk factors) (Kalil 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostatitis (chronic bacterial):</b> Oral, IV: 500 mg every 24 hours for 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections:</b> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Uncomplicated:</i> 500 mg every 24 hours for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Complicated:</i> 750 mg every 24 hours for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical (preoperative) prophylaxis (off-label use):</b> IV: 500 mg within 120 minutes prior to surgical incision (Bratzler 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical site infections (intestinal or genitourinary tract; perineum or axilla) (off-label use):</b> IV: 750 mg every 24 hours, in combination with metronidazole (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Traveler's diarrhea (off-label use):</b> Oral: 500 mg once daily for 1 to 3 days (ACG [Riddle 2016]; Riddle 2017). If symptoms not resolved after 24 hours following single dose therapy, continue with a 3-day therapy course. The 3-day therapy course is recommended in patients with fever or dysentery; enteric infection due to <i>Shigella dysenteriae</i> is an exception as a 5-day treatment duration appears to be superior to single-dose or 3-day regimens (ACG [Riddle 2016]). Adjunctive loperamide may be considered in patients receiving antibiotic therapy, in particular for immunocompetent adults with acute watery diarrhea (ACG [Riddle 2016]; IDSA [Shane 2017]; Riddle 2017). <b>Note:</b> Fluoroquinolone resistance is increasing; azithromycin may be preferred, particularly in regions such as southeast Asia or India with a high prevalence of <i>Campylobacter</i> (ACG [Riddle 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tuberculosis, drug-resistant tuberculosis, or intolerance to first-line agents (off-label use): </b>Oral: 500 to 1,000 mg every 24 hours (CDC 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urethritis, nongonococcal (off-label use):</b> Oral: 500 mg every 24 hours for 7 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infections:</b> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Uncomplicated:</i> 250 mg once daily for 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Complicated, including pyelonephritis:</i> 250 mg once daily for 10 days <b>or</b> 750 mg once daily for 5 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8406521\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=levofloxacin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Levofloxacin (systemic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute bacterial rhinosinusitis (off-label use):</b> Oral, IV: 10 to 20 mg/kg/day divided every 12 to 24 hours for 10 to 14 days (maximum: 500 mg daily). <b>Note:</b> Recommended in patients with a type I penicillin allergy, after failure of initial therapy or in patients at risk for antibiotic resistance (eg, daycare attendance, age &lt;2 years, recent hospitalization, antibiotic use within the past month) (Chow 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthrax (inhalational, postexposure): </b> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;6 months and Children &le;50 kg: 8 mg/kg every 12 hours for 60 days (do not exceed 250 mg/dose), beginning as soon as possible after exposure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;50 kg: 500 mg every 24 hours for 60 days, beginning as soon as possible after exposure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Chlamydia trachomatis</i> urogenital infection (alternative to preferred therapy) (off-label use):</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Community-acquired pneumonia (CAP) (IDSA/PIDS 2011):</b> <b>Note:</b> May consider addition of vancomycin or clindamycin to empiric therapy if community-acquired MRSA suspected; alternative to ceftriaxone or cefotaxime in patients not fully immunized for <i>H. influenzae</i> type b and <i>S. pneumoniae</i>, or significant local resistance to penicillin in invasive pneumococcal strains.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;6 months and Children &le;4 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. pneumoniae</i> (MICs to penicillin &le;2.0 mcg/mL), mild infection or step-down therapy (alternative to amoxicillin): Oral: 8 to 10 mg/kg/dose every 12 hours (maximum: 750 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. pneumoniae</i> (MICs to penicillin &ge;4.0 mcg/mL):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate-to-severe infection (alternative to ceftriaxone): IV: 8 to 10 mg/kg/dose every 12 hours (maximum: 750 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild infection, step-down therapy (preferred): Oral: 8 to 10 mg/kg/dose every 12 hours (maximum: 750 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>H. influenzae</i>, moderate-to-severe infection (alternative to ampicillin, ceftriaxone, or cefotaxime): IV: 8 to 10 mg/kg/dose every 12 hours (maximum: 750 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Atypical pathogens, moderate-to-severe infection (alternative to azithromycin) or empiric treatment (alternative to azithromycin +/- beta-lactam; should be limited to macrolide allergic/intolerant patients): Oral, IV: 8 to 10 mg/kg/dose every 12 hours (maximum: 750 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 5 to 16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. pneumoniae</i> (MICs to penicillin &le;2.0 mcg/mL), mild infection or step-down therapy (alternative to amoxicillin): Oral: 8 to 10 mg/kg/dose once daily (maximum: 750 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>S. pneumoniae</i> (MICs to penicillin &ge;4.0 mcg/mL):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate-to-severe infection (alternative to ceftriaxone): IV: 8 to 10 mg/kg/dose once daily (maximum: 750 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild infection, step-down therapy (preferred): Oral: 8 to 10 mg/kg/dose once daily (maximum: 750 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>H. influenzae</i>, moderate-to-severe infection (alternative to ampicillin, ceftriaxone, or cefotaxime): IV: 8 to 10 mg/kg/dose once daily (maximum: 750 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Atypical pathogens:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate-to-severe infection (alternative to azithromycin): Oral, IV: 8 to 10 mg/kg/dose once daily (maximum: 750 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild infection, step-down therapy (alternative to azithromycin in adolescents with skeletal maturity): Oral: 500 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Plague (prophylaxis and treatment): </b> Infants &ge;6 months and Children: Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&le;50 kg: 8 mg/kg every 12 hours for 10 to 14 days (do not exceed 250 mg/dose), beginning as soon as possible after exposure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;50 kg: 500 mg every 24 hours for 10 to 14 days, beginning as soon as possible after exposure. <b>Note:</b> Dose of 750 mg once daily may be considered if clinically warranted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical (preoperative) prophylaxis (off-label use):</b> Children &ge;1 year: IV: 10 mg/kg within 120 minutes prior to surgical incision (maximum: 500 mg) (Bratzler 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8406523\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8407064\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">IV, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Normal renal function dosing of 250 mg daily:</p>\n    <p style=\"text-indent:-4em;margin-left:6em;\">CrCl 20 to 49 mL/minute: No dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 19 mL/minute: Administer 250 mg every 48 hours (except in uncomplicated UTI, where no dosage adjustment is required).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis/chronic ambulatory peritoneal dialysis (CAPD): No information available.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Normal renal function dosing of 500 mg daily:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 20 to 49 mL/minute: Administer 500 mg initial dose, followed by 250 mg every 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 19 mL/minute: Administer 500 mg initial dose, followed by 250 mg every 48 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis/chronic ambulatory peritoneal dialysis (CAPD): Administer 500 mg initial dose, followed by 250 mg every 48 hours; supplemental doses are not required following either hemodialysis or CAPD</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Normal renal function dosing of 750 mg daily:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 20 to 49 mL/minute: Administer 750 mg every 48 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 19 mL/minute: Administer 750 mg initial dose, followed by 500 mg every 48 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis/chronic ambulatory peritoneal dialysis (CAPD): Administer 750 mg initial dose, followed by 500 mg every 48 hours; supplemental doses are not required following either hemodialysis or CAPD.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Normal renal function dosing of 750 or 1,000 mg daily (treatment of tuberculosis <b>only</b>) (CDC 2003): CrCl &lt;30 mL/minute: Administer 750 or 1,000 mg 3 times per week (in hemodialysis patients administer after dialysis on dialysis days).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CVVH: Loading dose of 500 to 750 mg followed by 250 mg every 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CVVHD: Loading dose of 500 to 750 mg followed by 250 to 500 mg every 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CVVHDF: Loading dose of 500 to 750 mg followed by 250 to 750 mg every 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15030188\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">IV, Oral: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). However, dosage adjustment unlikely due to limited hepatic metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8408135\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg/50 mL (50 mL); 500 mg/100 mL (100 mL); 750 mg/150 mL (150 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levaquin: 250 mg/50 mL (50 mL [DSC]); 500 mg/100 mL (100 mL [DSC]); 750 mg/150 mL (150 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg/50 mL (50 mL); 500 mg/100 mL (100 mL); 750 mg/150 mL (150 mL); 25 mg/mL (20 mL, 30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levaquin: 25 mg/mL (480 mL [DSC]) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg/mL (10 mL, 20 mL, 100 mL, 200 mL, 480 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levaquin: 250 mg, 500 mg, 750 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg, 750 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8398378\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8398367\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088619.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlGSE/KOjq2DWQecSYk0SGkg==&amp;TOPIC_ID=10214\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088619.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8407067\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Tablets may be administered without regard to meals. Oral solution should be administered at least 1 hour before or 2 hours after meals. Maintain adequate hydration of patient to prevent crystalluria. Administer at least 2 hours before or 2 hours after antacids containing magnesium or aluminum, sucralfate, metal cations (eg, iron), multivitamin preparations with zinc, or didanosine chewable/buffered tablets or the pediatric powder for solution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse 250 to 500 mg IV solution over 60 minutes; infuse 750 mg IV solution over 90 minutes. Too rapid of infusion can lead to hypotension. Avoid administration through an intravenous line with a solution containing multivalent cations (eg, magnesium, calcium). Maintain adequate hydration of patient to prevent crystalluria or cylindruria.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8400749\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of community-acquired pneumonia, including multidrug resistant strains of <i>S. pneumoniae</i> (MDRSP); nosocomial pneumonia; acute bacterial exacerbation of chronic bronchitis; acute bacterial rhinosinusitis (ABRS); prostatitis (chronic bacterial), urinary tract infection (uncomplicated or complicated); acute pyelonephritis; skin or skin structure infections (uncomplicated or complicated); reduce incidence or disease progression of inhalational anthrax (postexposure); prophylaxis and treatment of plague (pneumonic and septicemic) due to <i>Y. pestis</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Because fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions (eg, tendinitis and tendon rupture, peripheral neuropathy, CNS effects), reserve levofloxacin for use in patients who have no alternative treatment options for acute exacerbation of chronic bronchitis, acute bacterial sinusitis, and uncomplicated urinary tract infections.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25473214\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Bite wounds (animal/human); Chlamydia trachomatis infection; Community-acquired pneumonia (children); Diabetic foot infections; Epididymitis; Helicobacter pylori eradication; Intra-abdominal infections, complicated, community-acquired; Neutropenia (chemotherapy-induced), antibacterial prophylaxis; Pelvic inflammatory disease; Surgical prophylaxis; Surgical-site infections; Traveler's diarrhea; Tuberculosis; Urethritis (nongonococcal); Diverticulitis; Enterocolitis (Shigella spp); Legionnaires' disease; Peritonitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8398366\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levaquin may be confused with Levoxyl, Levsin/SL, Lovenox</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LevoFLOXacin may be confused with levETIRAcetam, levodopa, Levophed, levothyroxine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Levaquin [Argentina, Brazil, U.S., Venezuela] may be confused with Lariam brand name for mefloquine [multiple international markets]  </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8401454\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (1%), edema (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (6%), insomnia (4%), dizziness (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (2%), pruritus (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (7%), diarrhea (5%), constipation (3%), abdominal pain (2%), dyspepsia (2%), vomiting (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Vaginitis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Candidiasis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal electroencephalogram, abnormal gait, acute generalized exanthematous pustolosis, acute renal failure, ageusia, agitation, agranulocytosis, altered sense of smell, anaphylactoid reaction, anemia (including aplastic and hemolytic), anorexia, anosmia, anxiety, arthralgia, blurred vision, brain disease (rare), bronchospasm, cardiac arrest, cardiac arrhythmia (including ventricular tachycardia/fibrillation and torsades de pointes), casts in urine, <i>Clostridium difficile</i>-associated diarrhea, confusion, convulsions, crystalluria, decreased visual acuity, depression, dermatological disease, drowsiness, dysgeusia, elevation in serum levels of skeletal-muscle enzymes, eosinophilia, epistaxis, erythema multiforme, esophagitis, exacerbation of myasthenia gravis, fever, gastritis (including gastroenteritis), glossitis, granulocytopenia, hallucination, hepatic failure (some fatal), hepatic insufficiency, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014), hyperglycemia, hyperkalemia, hyperkinesia, hypersensitivity pneumonitis, hypersensitivity reaction (including anaphylaxis, angioedema, rash, pneumonitis, and serum sickness), hypertension, hypertonia, hypoacusis, hypoglycemia, hypotension, increased INR, increased intracranial pressure, increased serum alkaline phosphatase, increased serum transaminases, interstitial nephritis, intestinal obstruction, jaundice, leukocytosis, leukopenia, leukorrhea, lymphadenopathy, multiorgan failure, muscle injury, muscle spasm, myalgia, palpitations, pancreatitis, pancytopenia, paralysis, paranoia, paresthesia, peripheral neuropathy (may be irreversible), phlebitis, phototoxicity, prolonged prothrombin time, prolonged Q-T interval on ECG, pseudotumor cerebri, psychosis, renal function abnormality, restlessness, rhabdomyolysis, rupture of tendon, scotoma, seizure, skeletal pain, skin photosensitivity, sleep disorder (including abnormal dreams and nightmares), Stevens-Johnson syndrome, stomatitis, suicidal ideation, syncope, tachycardia, tendonitis, tinnitus, toxic epidermal necrolysis, toxic psychosis, thrombocytopenia (including thrombotic thrombocytopenic purpura), tremor, urticaria, uveitis, vasculitis (leukocytoclastic), vasodilatation, vertigo, visual disturbance (including diplopia), voice disorder</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8401447\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to levofloxacin, any component of the formulation, or other quinolones</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): History of tendonitis or tendon rupture associated with use of any quinolone antimicrobial agent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8401448\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered cardiac conduction: Fluoroquinolones may prolong QT<sub>c</sub> interval; avoid use in patients with a history of QT<sub>c</sub> prolongation, uncorrected hypokalemia, hypomagnesemia, or concurrent administration of other medications known to prolong the QT interval (including Class Ia and Class III antiarrhythmics, cisapride, erythromycin, antipsychotics, and tricyclic antidepressants).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glucose regulation: Fluoroquinolones have been associated with the development of serious, and sometimes fatal, hypoglycemia. These events have occurred most often in elderly patients with diabetes, but have also been reported in patients without a prior history of diabetes. Prompt identification and treatment of hypoglycemia is essential. Individual quinolones may differ in their potential to cause this effect. It was most evident with gatifloxacin (no longer marketed as systemic formulation). Hyperglycemia has also been associated with the use of fluoroquinolones. Patients should be monitored closely for signs/symptoms of disordered glucose regulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Unrelated to hypersensitivity, severe hepatotoxicity (including acute hepatitis and fatalities) has been reported. Elderly patients may be at greater risk. Discontinue therapy immediately if signs and symptoms of hepatitis occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis, have occurred with quinolone therapy. The spectrum of these reactions can vary widely; reactions may present as typical allergic symptoms (eg, itching, urticaria, rash, edema) after a single dose, or may manifest as severe idiosyncratic dermatologic (eg, Stevens-Johnson, toxic epidermal necrolysis), vascular (eg, vasculitis), pulmonary (eg, pneumonitis), renal (eg, nephritis), hepatic (eg, hepatic failure or necrosis), and/or hematologic (eg, anemia, cytopenias) events, usually after multiple doses. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phototoxicity: Avoid excessive sunlight and take precautions to limit exposure (eg, loose fitting clothing, sunscreen); may cause moderate-to-severe phototoxicity reactions. Discontinue use if photosensitivity occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serious adverse reactions:<b>[US Boxed Warning]: Fluoroquinolones are associated with disabling and potentially irreversible serious adverse reactions that may occur together, including tendinitis and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue levofloxacin immediately and avoid use of fluoroquinolones in patients who experience any of these serious adverse reactions.</b> Patients of any age or without preexisting risk factors have experienced these reactions; may occur within hours to weeks after initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- CNS effects: Fluoroquinolones have been associated with an increased risk of CNS effects including seizures, increased intracranial pressure (including pseudotumor cerebri), and toxic psychosis; may also cause nervousness, agitation, insomnia, anxiety, nightmares, paranoia, dizziness, confusion, tremors, hallucinations, depression, and suicidal thoughts or actions. May occur following the first dose; discontinue immediately and avoid further use of fluoroquinolones in patients who experience these reactions. Use with caution in patients with known or suspected CNS disorder, or risk factors that may predispose to seizures or lower the seizure threshold.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Peripheral neuropathy: Fluoroquinolones have been associated with an increased risk of peripheral neuropathy; may occur soon after initiation of therapy and may be irreversible; discontinue if symptoms of sensory or sensorimotor neuropathy occur. Avoid use in patients who have previously experienced peripheral neuropathy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Tendinitis/tendon rupture: Fluoroquinolones have been associated with an increased risk of tendonitis and tendon rupture in all ages; risk may be increased with concurrent corticosteroids, solid organ transplant recipients, and in patients &gt;60 years of age, but has also occurred in patients without these risk factors. Rupture of the Achilles tendon has been reported most frequently; but other tendon sites (eg, rotator cuff, biceps, hand) have also been reported. Inflammation and rupture may occur bilaterally. Cases have been reported within hours or days of initiation, and up to several months after discontinuation of therapy. Strenuous physical activity, renal failure, and previous tendon disorders may be independent risk factor for tendon rupture. Discontinue at first sign of tendon pain, swelling, inflammation or rupture. Avoid use in patients with a history of tendon disorders or who have experienced tendinitis or tendon rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: <b>[US Boxed Warning]: May exacerbate muscle weakness related to myasthenia gravis; avoid use in patients with known history of myasthenia gravis.</b> Cases of severe exacerbations, including the need for ventilatory support and deaths have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required. May increase risk of tendon rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may increase risk of tendon rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Adverse effects (eg, hepatotoxicity, tendon rupture, QT changes) may be increased in the elderly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; G6PD deficiency: Hemolytic reactions may (rarely) occur with quinolone use in patients with latent or actual G6PD deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Safety of use in pediatric patients for &gt;14 days of therapy has not been studied; increased incidence of musculoskeletal disorders (eg, arthralgia, tendon rupture) has been observed in children.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&quot;gasping syndrome&quot;) in neonates; the &quot;gasping syndrome&quot; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <b>[US Boxed Warning]: Reserve use of levofloxacin for treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, or uncomplicated urinary tract infection for patients who have no alternative treatment options because of the risk of disabling and potentially serious adverse reactions (eg, tendinitis and tendon rupture, peripheral neuropathy, CNS effects).</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299595\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8401459\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10214&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the absorption of Quinolones. Of concern only with oral administration of quinolones. Management: Avoid concurrent administration of quinolones and antacids to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone.<b> Exceptions: </b>Sodium Bicarbonate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Glucose Lowering Agents: Quinolones may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May decrease the absorption of Quinolones. Of concern only with oral administration of both agents.<b> Exceptions: </b>Calcium Chloride.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delamanid: Quinolones may enhance the QTc-prolonging effect of Delamanid.  Management: Avoid concomitant use of delamanid and quinolone antibiotics if possible. If coadministration is considered to be unavoidable, frequent monitoring of electrocardiograms (ECGs) throughout the full delamanid treatment period should occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: Quinolones may decrease the serum concentration of Didanosine. Didanosine may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heroin: Quinolones may enhance the adverse/toxic effect of Heroin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for levo-, nor-, oflox-, pefloxacin, or nalidixic acid) oral iron salts<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Quinolones. Management: Administer oral quinolone antibiotics at least one hour before or four hours after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the serum concentration of Quinolones. Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Quinolones. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Quinolones. Specifically, minerals in the multivitamin/mineral product may impair absorption of quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Quinolones may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nadifloxacin: May enhance the adverse/toxic effect of Quinolones.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May decrease the excretion of Quinolones. Specifically, probenecid may decreased the renal excretion of quinolone antibiotics. Probenecid may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinapril: May decrease the serum concentration of Quinolones. Management: Separate doses of quinapril and oral quinolones by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the quinolone if these products are used concomitantly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sevelamer: May decrease the absorption of Quinolones. Management: Administer oral quinolones at least 2 hours before or 6 hours after sevelamer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strontium Ranelate: May decrease the serum concentration of Quinolones. Management: In order to minimize any potential impact of strontium ranelate on quinolone antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during quinolone therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May decrease the serum concentration of Quinolones. Management: Administer oral quinolones at least 2 hours before or 6 hours after the sucralfate dose.  Greater separation of doses may further lessen the risk for a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): LevoFLOXacin (Systemic) may enhance the QTc-prolonging effect of Tacrolimus (Systemic). LevoFLOXacin (Systemic) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varenicline: Quinolones may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concurrent use of levofloxacin or other quinolone antibiotics, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Quinolones may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zinc Salts: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for levo-, nor-, pe- or ofloxacin or nalidixic acid) oral zinc salts.<b> Exceptions: </b>Zinc Chloride.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51073434\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Administration with food prolonged time to peak by ~1 hour and decreased the peak concentration by ~14% and ~25% for the tablet and oral solution, respectively. Management: Tablet may be administered without regard to food; oral solution should be administered at least 1 hour before or 2 hours after food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8400751\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8400752\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Levofloxacin crosses the placenta and can be detected in the amniotic fluid and cord blood (Ozy&uuml;nc&uuml; 2010a; Ozy&uuml;nc&uuml; 2010b). Information specific to levofloxacin use during pregnancy is limited (Padberg 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8401446\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;\">Levofloxacin is excreted in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The relative infant dose (RID) of levofloxacin is 6% when calculated using the highest breast milk concentration located and compared to a therapeutic infant dose of 20 mg/kg/day. In general, breast-feeding is considered acceptable when the relative infant dose is &lt;10% (Anderson 2016; Ito 2000). Using the highest milk concentration (8.2 mcg/mL), the estimated daily infant dose via breast milk is 1.23 mg/kg/day. This milk concentration was obtained following a maternal dose of IV levofloxacin 500 mg/day on day 10 of therapy; the half-life in the breast milk was approximately 7 hours (Cahill 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora. Monitor infants for GI disturbances (WHO 2002). The manufacturer does not recommend use of levofloxacin in nursing women due to concerns of serious adverse reactions. The risk of articular damage in nursing infants exposed to other quinolones (ie, ciprofloxacin) is considered low even in children receiving high therapeutic doses. Therefore, some sources do not consider maternal use of these agents to be a reason to discontinue nursing as long as the infant is monitored for gastrointestinal symptoms (eg, diarrhea) which could occur following antibiotic exposure (Kaplan 2015). Other sources recommend avoiding quinolone antibiotics if alternative agents are available (WHO 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8407066\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Tablets may be taken without regard to meals. Oral solution should be administered on an empty stomach (at least 1 hour before or 2 hours after a meal).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8407071\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Evaluation of organ system functions (renal, hepatic, and hematopoietic) is recommended periodically during therapy; the possibility of crystalluria should be assessed; WBC and signs of infection, altered mental status, signs and symptoms of tendonitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8404710\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">As the S(-) enantiomer of the fluoroquinolone, ofloxacin, levofloxacin, inhibits DNA-gyrase in susceptible organisms thereby inhibits relaxation of supercoiled DNA and promotes breakage of DNA strands. DNA gyrase (topoisomerase II), is an essential bacterial enzyme that maintains the superhelical structure of DNA and is required for DNA replication and transcription, DNA repair, recombination, and transposition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8404755\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid and complete; levofloxacin oral tablet and solution formulations are bioequivalent </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely distributed in the body, including blister fluid, skin tissue, macrophages, prostate, and lung tissue; CSF concentrations ~15% of serum concentrations </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">V<sub>d</sub>: (Chien 2005):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants &ge;6 months, Children, and Adolescents &le;16 years: Mean range: 1.44 to 1.57 L/kg; reported values not statistically different between pediatric age subgroups; distribution not age-dependent </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 1.27 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~24% to 38%; primarily to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Minimally hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants &ge;6 months and Children &le;5 years: ~4 hours (Chien 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 5 to 10 years: 4.8 hours (Chien 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 10 to 12 years: 5.4 hours (Chien 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 12 to 16 years: 6 hours (Chien 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: ~6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults, renal impairment: 27 &plusmn; 10 hours (CrCl 20 to 49 mL/minute); 35 &plusmn; 5 hours (CrCl &lt;20 mL/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~87% as unchanged drug, &lt;5% as metabolites); feces (&lt;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance: IV (Chien 2005): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children 6 months to 2 years: 0.35 &plusmn; 0.13 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 5 years: 0.32 &plusmn; 0.08 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 5 to 10 years: 0.25 &plusmn; 0.05 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 10 to 12 years: 0.19 &plusmn; 0.05 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 12 to 16 years: 0.18 &plusmn; 0.03 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 0.15 &plusmn; 0.02 L/hour/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8408137\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LevoFLOXacin in D5W Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/50 mL (50 mL): $7.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/100 mL (100 mL): $7.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg/150 mL (150 mL): $7.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LevoFLOXacin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (20 mL): $19.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LevoFLOXacin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (10 mL): $15.14</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Levaquin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (50): $1,572.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (50): $1,802.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (20): $1,349.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (LevoFLOXacin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (50): $840.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (50): $963.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (20): $721.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961985\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adlox (IN);</li>\n      <li>Amlevo (VN);</li>\n      <li>Astefor (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Auxxil (CL, PY);</li>\n      <li>Avoxin (JO);</li>\n      <li>Axoflon (PH);</li>\n      <li>Bacflocin (TW);</li>\n      <li>Bactevo (VN);</li>\n      <li>Bredelin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Conlevo (EC);</li>\n      <li>Corvox (ID);</li>\n      <li>Cravit (CN, HK, ID, JP, MY, PK, SG, TH, TW, VN);</li>\n      <li>Cravox (ID);</li>\n      <li>Elequine (BB, BM, BS, EC, JM, NL, PR, SR, TT);</li>\n      <li>Evocs-III (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Evolox (RO);</li>\n      <li>Evoxil (MT);</li>\n      <li>Fenalex (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Flexid (HR);</li>\n      <li>Floxacap (ID);</li>\n      <li>Floxel (PH);</li>\n      <li>Getzlox (VN);</li>\n      <li>Glevo (ZW);</li>\n      <li>Glevo IV (PH);</li>\n      <li>Gravixin (TH);</li>\n      <li>Hailon (CN);</li>\n      <li>Lamiwin (TZ);</li>\n      <li>Lecifex (VN);</li>\n      <li>Lecrav (ID);</li>\n      <li>Lectacin (VN);</li>\n      <li>Leflodal (TW);</li>\n      <li>Leflox (BD);</li>\n      <li>Lefloxin (TH);</li>\n      <li>Lefocin (KR);</li>\n      <li>Lemed (HK);</li>\n      <li>LEO (BD);</li>\n      <li>Leroxacin (KR);</li>\n      <li>Lesacin (KR);</li>\n      <li>Levaquin (AR, BR, CO, PE);</li>\n      <li>Levo (IL);</li>\n      <li>Levobact (PH);</li>\n      <li>Levocin (ID, PH, TH);</li>\n      <li>Levoflox (QA, ZW);</li>\n      <li>Levokacin (KR);</li>\n      <li>Levoksa (UA);</li>\n      <li>Levomac (ET, ZW);</li>\n      <li>Levomicin (KR);</li>\n      <li>Levon (PH);</li>\n      <li>Levoquin (HK, PH);</li>\n      <li>Levores (ID);</li>\n      <li>Levotsyn (UA);</li>\n      <li>Levox (JO, LK, PH, QA, ZW);</li>\n      <li>Levoxa (MT);</li>\n      <li>Levoxacin (IT);</li>\n      <li>Levoxin (HK);</li>\n      <li>Levoxl (HK);</li>\n      <li>Levunid (PE);</li>\n      <li>Lexacin (HK);</li>\n      <li>Lexlo (BD);</li>\n      <li>Locikline (MY);</li>\n      <li>Lovequin (ID);</li>\n      <li>Loxof (LB);</li>\n      <li>Lufi (LK);</li>\n      <li>LUFI-500 (SG);</li>\n      <li>Matador (LB);</li>\n      <li>Mosardal (ID);</li>\n      <li>Nexquin (TZ);</li>\n      <li>Nirliv (TH);</li>\n      <li>Nirlix (LK);</li>\n      <li>Nislev (ID);</li>\n      <li>Nofaxin (KR);</li>\n      <li>Olfovel (TH);</li>\n      <li>Omnivox (PH);</li>\n      <li>Pneumocal (PH);</li>\n      <li>Ponaris (PE);</li>\n      <li>Quinomed L (AR);</li>\n      <li>Qure (ET);</li>\n      <li>Reskuin (ID);</li>\n      <li>Resquin (LK);</li>\n      <li>Rinvox (ID);</li>\n      <li>Rozoxin (TW);</li>\n      <li>Tavager (IE);</li>\n      <li>Tavanic (AE, AR, AT, BE, BG, BH, BM, BS, CH, CL, CR, CY, CZ, DE, DO, EE, EG, ES, FI, FR, GB, GT, HN, IE, IL, JM, JO, KW, LB, LT, LU, MT, NI, NL, PA, PE, PL, PT, PY, QA, RO, SA, SE, SK, SV, VE);</li>\n      <li>Truxa (EC, UY);</li>\n      <li>Uroflox (EC);</li>\n      <li>Vocin (TH);</li>\n      <li>Voflox (TH);</li>\n      <li>Volequin (ID);</li>\n      <li>VoLox (ID);</li>\n      <li>Vorotal (TW);</li>\n      <li>Wilovex (PH);</li>\n      <li>Xalecin (TH);</li>\n      <li>Zidalex (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al. &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16148283\"></a>Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. <i>N Engl J Med</i>. 2005;353(10):977-987.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/16148283/pubmed\" target=\"_blank\" id=\"16148283\">16148283</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cahill JB Jr, Bailey EM, Chien S, et al, &quot;Levofloxacin Secretion in Breast Milk: A Case Report,&quot; <i>Pharmacotherapy</i>, 2005, 25(1):116-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/15767227/pubmed\" target=\"_blank\" id=\"15767227\">15767227</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &quot;Sexually Transmitted Diseases Treatment Guidelines, 2006,&quot; <i>MMWR</i>, 2006, 55(RR-11): 1-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/16760892/pubmed\" target=\"_blank\" id=\"16760892\">16760892</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention. The pre-travel consultation: travelers' diarrhea. The Yellow Book: CDC health information for international travel, 2018. <a href=\"https://wwwnc.cdc.gov/travel/yellowbook/2018/the-pre-travel-consultation/travelers-diarrhea\" target=\"_blank\">https://wwwnc.cdc.gov/travel/yellowbook/2018/the-pre-travel-consultation/travelers-diarrhea</a>. Updated June 13, 2017. Accessed September 6, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &ldquo;Treatment of Tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America,&rdquo; 2003, <i>MMWR Recomm Rep</i>, 52(RR-11):3-5. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/12836625/pubmed\" target=\"_blank\" id=\"12836625\">12836625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &ldquo;Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones No Longer Recommended for Treatment of Gonococcal Infections,&rdquo; <i>MMWR Recomm Rep</i>, 2007, 56(14):332-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/17431378/pubmed\" target=\"_blank\" id=\"17431378\">17431378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of <i>Helicobacter pylori</i> infection. <i>Am J Gastroenterol</i>. 2017;112(2):212-239. doi: 10.1038/ajg.2016.563<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/28071659/pubmed\" target=\"_blank\" id=\"28071659\">28071659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chey WD and Wong B, &ldquo;American College of Gastroenterology Guideline on the Management of <i>Helicobacter pylori</i> Infection,&rdquo; <i>Am J Gastroenterol</i>, 2007 102(8):1808-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/17608775/pubmed\" target=\"_blank\" id=\"17608775\">17608775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chien S, Wells TG, Blumer JL, et al. Levofloxacin pharmacokinetics in children. <i>J Clin Pharmacol</i>. 2005;45(2):153-160.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/15647407/pubmed\" target=\"_blank\" id=\"15647407\">15647407</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo; <i>Clin Infect Dis</i>, 2012, 54(8):e72-112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16148284\"></a>Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. <i>N Engl J Med</i>. 2005;353(10):988-998.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/16148284/pubmed\" target=\"_blank\" id=\"16148284\">16148284</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. <i>Clin Infect Dis</i>. 2011;52(4):e56-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/21258094/pubmed\" target=\"_blank\" id=\"21258094\">21258094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedrich LV and Dougherty R, &ldquo;Fatal Hypoglycemia Associated With Levofloxacin,&rdquo; <i>Pharmacotherapy</i>, 2004, 24(12):1807-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/15585448/pubmed\" target=\"_blank\" id=\"15585448\">15585448</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frothingham R, &ldquo;Glucose Homeostasis Abnormalities Associated With Use of Gatifloxacin,&rdquo; <i>Clin Infect Dis</i>, 2005, 41(9):1269-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/16206101/pubmed\" target=\"_blank\" id=\"16206101\">16206101</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gavin JR 3rd, Kubin R, Choudhri S, et al, &ldquo;Moxifloxacin and Glucose Homeostasis: A Pooled-Analysis of the Evidence From Clinical and Postmarketing Studies,&rdquo; <i>Drug Saf</i>, 2004, 27(9):671-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/15230648/pubmed\" target=\"_blank\" id=\"15230648\">15230648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. <i>Clin Infect Dis</i>. 2002;35(4):381-389.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/12145720/pubmed\" target=\"_blank\" id=\"12145720\">12145720</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Graumlich JF, Habis S, Avelino RR, et al, &ldquo;Hypoglycemia in Inpatients After Gatifloxacin or Levofloxacin Therapy: Nested Case-Control Study,&rdquo; <i>Pharmacotherapy</i>, 2005, 25(10):1296-302.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/16185172/pubmed\" target=\"_blank\" id=\"16185172\">16185172</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society [published online July 14, 2016]. <i>Clin Infect Dis</i>. doi: 10.1093/cid/ciw353.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/27418577/pubmed\" target=\"_blank\" id=\"27418577\">27418577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaplan YC, Koren G. Use of ciprofloxacin during breastfeeding. <i>Can Fam Physician</i>. 2015;61(4):343-344.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/26052598/pubmed\" target=\"_blank\" id=\"26052598\">26052598</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khaliq Y and Zhanel GG, &ldquo;Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature,&rdquo; <i>Clin Infect Dis</i>, 2003, 36(11):1404-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/12766835/pubmed\" target=\"_blank\" id=\"12766835\">12766835</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lawrence KR, Adra M, and Keir C, &ldquo;Hypoglycemia-Induced Anoxic Brain Injury Possibly Associated With Levofloxacin,&rdquo; <i>J Infect</i>, 2006, 52(6):e177-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/16269178/pubmed\" target=\"_blank\" id=\"16269178\">16269178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levaquin (levofloxacin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levofloxacin injection [prescribing information]. Schaumburg, IL: Sagent Pharmaceuticals; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levofloxacin [product monograph]. Boucherville, QC, Canada: Sandoz Canada; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Cornia PB, et al, &quot;2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,&quot; <i>Clin Infect Dis</i>, 2012, 54(12):e132-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/22619242/pubmed\" target=\"_blank\" id=\"22619242\">22619242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malone RS, Fish DN, Abraham E, et al, &ldquo;Pharmacokinetics of Levofloxacin and Ciprofloxacin During Continuous Renal Replacement Therapy in Critically Ill Patients,&rdquo; <i>Antimicrob Agents Chemother</i>, 2001, 45(10):2949-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/11557500/pubmed\" target=\"_blank\" id=\"11557500\">11557500</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. <i>Clin Infect Dis</i>. 2007;44 Suppl 2:S27-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/17278083/pubmed\" target=\"_blank\" id=\"17278083\">17278083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. Emerg Infect Dis. 2014;20(2). Available at http://dx.doi.org/10.3201/eid2002.130611</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mohr JF, McKinnon PS, Peymann PJ, et al, &ldquo;A Retrospective, Comparative Evaluation of Dysglycemias in Hospitalized Patients Receiving Gatifloxacin, Levofloxacin, Ciprofloxacin, or Ceftriaxone,&rdquo; <i>Pharmacotherapy</i>, 2005, 25(10):1303-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/16185173/pubmed\" target=\"_blank\" id=\"16185173\">16185173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicolle LN, Bradley S, Colgan R et al, &ldquo;Infectious Disease Society of America Guidelines for the Diagnosis and Treatment of Asymptomatic Bacteriuria in Adults,&rdquo; <i>Clinical Infectious Diseases</i>, 2005, 40:643-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/15714408/pubmed\" target=\"_blank\" id=\"15714408\">15714408</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozy&uuml;nc&uuml; O, Beksac MS, Nemutlu E, Katlan D, Kir S. Maternal blood and amniotic fluid levels of moxifloxacin, levofloxacin and cefixime. <i>J Obstet Gynaecol Res</i>. 2010a;36(3):484-487.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/20598025 /pubmed\" target=\"_blank\" id=\"20598025 \">20598025 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozy&uuml;nc&uuml; O, Nemutlu E, Katlan D, Kir S, Beksac MS. Maternal and fetal blood levels of moxifloxacin, levofloxacin, cefepime and cefoperazone. <i>Int J Antimicrob Agents</i>. 2010b;36(2):175-178.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/20418070 /pubmed\" target=\"_blank\" id=\"20418070 \">20418070 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Padberg S, Wacker E, Meister R, et al. Observational cohort study of pregnancy outcome after first-trimester exposure to fluoroquinolones. <i>Antimicrob Agents Chemother</i>. 2014;58(8):4392-4398.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/24841264 /pubmed\" target=\"_blank\" id=\"24841264 \">24841264 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park-Wyllie LY, Juurlink DN, Kopp A, et al, &ldquo;Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults,&rdquo; <i>N Engl J Med</i>, 2006, 354(13):1352-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/16510739/pubmed\" target=\"_blank\" id=\"16510739\">16510739</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riddle MS, Connor BA, Beeching NJ, et al. Guidelines for the prevention and treatment of travelers&rsquo; diarrhea: a graded expert panel report. <i>J Travel Med.</i> 2017;24(suppl 1):S57-S74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/28521004/pubmed\" target=\"_blank\" id=\"28521004\">28521004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riddle MS, DuPont HL, Connor BA. ACG Clinical Guideline: diagnosis, treatment, and prevention of acute diarrheal infections in adults. <i>Am J Gastroenterol</i>. 2016;111(5):602-622. doi: 10.1038/ajg.2016.126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/27068718/pubmed\" target=\"_blank\" id=\"27068718\">27068718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sedlak T, Shufelt C, Iribarren C, et al, &quot;Oral Contraceptive Use and the ECG: Evidence of an Adverse QT Effect on Corrected QT Interval,&quot; <i>Ann Noninvasive Electrocardiol</i>, 2013, 18(4):389-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/23879279/pubmed\" target=\"_blank\" id=\"23879279\">23879279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. <i>Clin Infect Dis.</i> 2017;65(12):e45-e80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/29053792/pubmed\" target=\"_blank\" id=\"29053792\">29053792</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Szarfman A, Chen M, and Blum MD, &ldquo;More on Fluoroquinolone Antibiotics and Tendon Rupture,&rdquo; <i>N Engl J Med</i>, 1995, 332(3):193.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo; <i> Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang S and Rizvi AA, &ldquo;Levofloxacin-Induced Hypoglycemia in a Nondiabetic Patient,&rdquo; <i>Am J Med Sci</i>, 2006, 331(6):334-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/16775443/pubmed\" target=\"_blank\" id=\"16775443\">16775443</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zacher JL and Givone DM, &ldquo;False-Positive Urine Opiate Screening Associated With Fluoroquinolone Use,&rdquo; <i>Ann Pharmacother</i>, 2004, 38:1525-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levofloxacin-systemic-drug-information/abstract-text/15252190/pubmed\" target=\"_blank\" id=\"15252190\">15252190</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10214 Version 283.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8398365\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8398376\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8398377\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8398383\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8406522\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F8406521\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8406523\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F8407064\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15030188\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8408135\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F8398378\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F8398367\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F8407067\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8400749\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25473214\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8398366\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8401454\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8401447\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8401448\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299595\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8401459\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F51073434\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8400751\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8400752\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F8401446\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F8407066\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F8407071\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8404710\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F8404755\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8408137\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961985\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10214|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=levofloxacin-systemic-patient-drug-information\" class=\"drug drug_patient\">Levofloxacin (systemic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=levofloxacin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Levofloxacin (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}